innovative ways of assessing durable responses to...
TRANSCRIPT
![Page 1: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/1.jpg)
Innovative ways of assessing durable responses to immunotherapy Prof. Christophe Le Tourneau, MD, PhD
Head, Department of Drug Development & Innovation (D3i)
Institut Curie, Paris, France
Paris-Saclay University
WIN consortium – Paris – June 23, 2019 1
![Page 2: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/2.jpg)
Disclosures
• Participation in advisory boards:
MSD, BMS, Merck Serono, GSK, Astra Zeneca, Nanobiotix, Amgen, Roche
2
![Page 3: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/3.jpg)
Introduction
• Immunotherapy targeting the PD1/PD-L1 axis has been a breakthrough in oncology for several reasons:
- novelty of the mechanism of action
- efficacy in multiple tumor types
- occurrence of durable responses
3
![Page 4: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/4.jpg)
Melanoma patients treated with ipilumumab
4 Schadendorf et al., JCO 2015;33:1889-94
![Page 5: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/5.jpg)
NSCLC patients treated with nivolumab
5 Gettinger et al., JCO 2018;36:1675-84
![Page 6: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/6.jpg)
NSCLC patients treated with nivolumab
6 Gettinger et al., JCO 2018;36:1675-84
![Page 7: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/7.jpg)
Challenges
• How to define a durable response?
7
![Page 8: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/8.jpg)
How to define a durable response?
• No definition
8
![Page 9: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/9.jpg)
How to define a durable response?
• No definition
• Exceptional responders initiative:
Received a treatment in which fewer than 10% of patients had a CR or a durable PR > 6 months
9 https://www.cancer.gov/about-cancer/treatment/research/exceptional-responders-initiative-qa
![Page 10: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/10.jpg)
How to define a durable response?
10 Borcoman et al., Ann Oncol 2019;30:385-396
![Page 11: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/11.jpg)
How to define a durable response?
11 Ferris et al., NEJM 2016;375:1856-67; Robert et al., 2015;372:320-30
HNSCC Melanoma
![Page 12: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/12.jpg)
How to define a durable response?
12
Durable response =
PFS > 3x median PFS
of the whole cohort
Pons et al., JCO Precis Oncol 2019
![Page 13: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/13.jpg)
Challenges
• How to define a durable response?
• How frequent are durable responses?
13
![Page 14: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/14.jpg)
How frequent are durable responses?
• Meta analysis of randomized phase III trials that included at least one immunotherapy arm in the R/M setting
• 19 trials
• 11,640 patients
• 42 arms:
- 26 immunotherapy arms
- 16 non-immunotherapy arms
14 Pons et al., JCO Precis Oncol 2019
![Page 15: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/15.jpg)
How frequent are durable responses?
15 Pons et al., JCO Precis Oncol 2019
25%
11%
![Page 16: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/16.jpg)
Challenges
• How to define a durable response?
• How frequent are durable responses?
• How to predict a durable response?
16
![Page 17: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/17.jpg)
How to predict a durable response?
• Multivariate analysis:
17
Variables Coef. [95% CI] P value
Type of ICI:
Anti-PD1/PD-L1 agents
Anti-CTLA4 agents
1
0.73 [0.52 – 0.94]
<0.0001
Line of therapy:
First-line
Beyond first-line
1
0.29 [0.05 – 0.52]
0.02
Tumor type:
Melanoma
Non-melanoma
1
-0.02 [-0.26 – 0.22]
0.85
Pons et al., JCO Precis Oncol 2019
![Page 18: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/18.jpg)
How to predict a durable response?
18 Tan et al., Ann Oncol 2018;29:2115-20
CT scan PET-CT
![Page 19: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/19.jpg)
Challenges
• How to define a durable response?
• How frequent are durable responses?
• How to predict a durable response?
• Should treatment be interrupted?
19
![Page 20: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/20.jpg)
Should treatment be interrupted?
20 Spigel et al., ESMO 2017 (#12970)
• Checkmate 153
![Page 21: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/21.jpg)
Should treatment be interrupted?
21 Spigel et al., ESMO 2017 (#12970)
![Page 22: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/22.jpg)
Should treatment be interrupted?
• ORR following drug rechallenge:
22
Tumor type Drug ORR (%) Reference
Melanoma Pembrolizumab 25% Lebbé Ann Oncol 2014
Melanoma Ipilimumab 19%
12%
23%
Robert ASCO 2017
Robert CCR 2013
Chiarion-Sileni BJC 2014
All Anti-PD1/PD-L1 25% Bernard-Tessier EJC 2018
Borcoman et al., Ann Oncol 2019;30:385-396
![Page 23: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/23.jpg)
Should treatment be interrupted?
• Severe toxicity
23
![Page 24: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/24.jpg)
Should treatment be interrupted?
• Severe toxicity
• Remaining open questions:
- Should treatment be interrupted after achieving a CR? a PR?
- How long after achieving a CR (a PR?) treatment should be interrupted?
24
![Page 25: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/25.jpg)
Challenges
• How to define a durable response?
• How frequent are durable responses?
• How to predict a durable response?
• Should treatment be interrupted?
• How to select patients for single agent immunotherapy?
25
![Page 26: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/26.jpg)
How to select patients for single agent immunotherapy?
26
![Page 27: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/27.jpg)
How to select patients for single agent immunotherapy?
27
![Page 28: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/28.jpg)
How to select patients for single agent immunotherapy?
28
![Page 29: Innovative ways of assessing durable responses to ...winconsortium.org/files/Le_Tourneau_WIN_23062019.pdf · Conclusions •Defining durable responders as patients experiencing a](https://reader033.vdocuments.site/reader033/viewer/2022051909/5ffd42c167fbaa7628428bf3/html5/thumbnails/29.jpg)
Conclusions
• Defining durable responders as patients experiencing a PFS that exceeds 3x the median PFS of the whole population is a nice way to overcome patients’ heterogeneity
• Durable responses are more frequent with immunotherapy then with other anticancer agents but are not specific to immunotherapy
• Durable responses may be more frequent in less advanced disease
• Patients achieving CR according to RECIST or complete metabolic response on PET CT are more prone to experience a durable response
29